tianeptine has been researched along with valproic acid in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Fisar, Z; Hroudová, J; Raboch, J | 1 |
| Benet, M; Castell, JV; Donato, MT; García-Mediavilla, MV; Guzmán, C; Jover, R; Martínez-Chantar, ML; Pisonero-Vaquero, S; Sánchez-Campos, S | 1 |
5 other study(ies) available for tianeptine and valproic acid
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.
Topics: Affect; Amitriptyline; Animals; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Cerebral Cortex; Citalopram; Clorgyline; Cocaine; Cyclohexanols; Desipramine; Fluoxetine; Imipramine; In Vitro Techniques; Iproniazid; Lithium; Mianserin; Mirtazapine; Mitochondria; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Morpholines; Olanzapine; Pargyline; Reboxetine; Swine; Thiazepines; Valproic Acid; Venlafaxine Hydrochloride | 2010 |
Repression of the nuclear receptor small heterodimer partner by steatotic drugs and in advanced nonalcoholic fatty liver disease.
Topics: Animals; CCAAT-Enhancer-Binding Protein-alpha; Cells, Cultured; Cyclosporine; Doxycycline; Fatty Liver; Humans; Male; Mice; Mitogen-Activated Protein Kinase 1; Non-alcoholic Fatty Liver Disease; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Tetracycline; Thiazepines; Transcription, Genetic; Valproic Acid | 2015 |